Medpace (NASDAQ:MEDP) Issues Quarterly Earnings Results, Beats Estimates By $0.61 EPS

Medpace (NASDAQ:MEDP - Get Free Report) announced its quarterly earnings results on Monday. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61, Zacks reports. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period in the prior year, the business earned $3.20 earnings per share. Medpace updated its FY 2025 guidance to 12.260-13.040 EPS.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $10.17 during midday trading on Thursday, hitting $300.71. 254,719 shares of the stock traded hands, compared to its average volume of 434,036. Medpace has a one year low of $250.05 and a one year high of $459.77. The business has a 50 day moving average price of $315.38 and a two-hundred day moving average price of $332.24. The company has a market cap of $9.09 billion, a PE ratio of 23.85, a P/E/G ratio of 3.81 and a beta of 1.46.

Analyst Ratings Changes

Several brokerages recently issued reports on MEDP. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and lowered their target price for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Robert W. Baird lowered their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday. Mizuho reduced their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Truist Financial decreased their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday. Finally, Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.